Turning Lower Prices into Patient Affordability: A Global Policy Challenge
The ISPOR Monthly Policy Brief provides concise insights into emerging developments shaping the global health policy landscape. Each edition highlights timely issues relevant to the health economics and outcomes research (HEOR) community and beyond, examining how evolving policy decisions influence healthcare systems, evidence generation, innovation, and patient access. View all Policy Briefs here.
Ana Amaris, MD, MPH, Director, Health Policy Initiatives, ISPOR
Overview: Pharmaceutical policy discussions frequently emphasize medicine prices, yet their implications for patients depend on more than pricing alone. This distinction echoes a question raised in ISPOR's earlier brief on emerging pharmaceutical policy signals: whether savings achieved by governments and payers necessarily translate into patient benefits. Building on October's examination of pharmaceutical innovation, this edition turns to another dimension of pharmaceutical policy: how different approaches influence patients' ability to afford treatment.
The question is particularly timely. Recent US initiatives offering discounted prescription medicines directly to consumers have renewed attention to patient-facing prices, while European countries continue to refine reimbursement and financial protection policies. These developments offer an opportunity to examine how affordability objectives are pursued across different health systems.
From Medicine Prices to Patient Costs
In February 2026, the US government launched TrumpRx, a platform connecting consumers with discounted cash-pay offers for selected prescription medicines. While these arrangements may provide lower-cost purchasing options, their financial implications depend on individual circumstances. As KFF’s analysis explains, patients may sometimes find lower prices than those on TrumpRx through insurance or other available alternatives, while discounted purchases made outside insurance generally do not contribute toward deductibles or annual out-of-pocket limits.
The international dimension of pharmaceutical pricing has also attracted renewed attention. A recent Egmont Institute paper examines how US and European pricing institutions differ and how policies linking prices across markets could affect pharmaceutical expenditure. Although these debates primarily concern prices paid by purchasers, they highlight the importance of understanding the financing arrangements within which pricing policies operate.
Different Pathways to Patient Affordability
Countries pursue affordability through distinct mechanisms, including price regulation, purchasing arrangements, pharmaceutical coverage, and limits on patient cost sharing. Because these interventions operate through different mechanisms, their reported outcomes should not be interpreted as equivalent measures of effectiveness. They nevertheless offer useful insights into how different policy choices seek to reduce patients' financial burdens.
In Europe, financial protection policies demonstrate how affordability can be addressed without necessarily changing a medicine's underlying price. A WHO/Europe assessment examines income-based caps on patient payments in Austria, Belgium, Germany, and Spain, highlighting their potential to protect lower-income households while underscoring that additional measures are needed to address persistent financial hardship and barriers to care. More recently, Spain’s May 2026 pharmaceutical copayment reform introduced more differentiated income categories and revised monthly payment limits, illustrating continued efforts to align patient contributions with financial capacity.
However, public coverage does not always provide sufficient financial protection. A 2025 WHO assessment of Portugal identified outpatient medicines as a major contributor to catastrophic health spending, particularly among lower-income households. Percentage-based copayments, gaps in coverage, and the absence of an overall copayment cap were among the factors contributing to financial hardship.
Beyond Europe, Chile illustrates another approach. Through its Cenabast Law, centralized pharmaceutical purchasing supports the supply of medicines to participating private pharmacies at regulated maximum retail prices. Government reporting indicates substantial consumer price savings compared with nonparticipating pharmacies. Although these comparisons do not establish broader improvements in treatment access or health outcomes, they illustrate a mechanism designed to influence the retail prices patients encounter.
Measuring Patient Benefits: The Role of HEOR
These experiences raise an important question for health economics and outcomes research: How can policy makers determine whether affordability interventions deliver their intended patient benefits?
Price reductions, procurement savings, and changes in pharmaceutical expenditure remain important indicators of financial performance, but evaluating patient affordability also requires evidence on actual out-of-pocket payments, financial hardship, medicine utilization, and equity.
The appropriate evaluation approach depends on the intervention. Discounted cash-pay arrangements call for comparisons with patients’ available purchasing alternatives; copayment protections require analysis of household financial exposure; and retail pricing interventions warrant assessment of transaction prices, availability, and participation. Across these approaches, distributional analyses can help identify who benefits, who remains financially exposed, and whether changes in affordability are associated with improved access to treatment.
Looking Ahead
As pharmaceutical pricing and financing policies evolve, their success should be assessed against the objectives they are designed to achieve. For policy makers, this means considering how pricing decisions interact with coverage, cost sharing, and financial protection. For the HEOR community, it presents an opportunity to strengthen patient-centered evaluations that distinguish announced or anticipated savings from benefits demonstrated in practice.
Ultimately, understanding—and improving—pharmaceutical affordability requires looking beyond price changes to examine whether patients can obtain the medicines they need without undue financial hardship.